Drug Profile
Sirolimus-eluting coronary stent - JW Medical Systems
Alternative Names: Excel; Excel DES; Excel-IILatest Information Update: 30 Dec 2021
Price :
$50
*
At a glance
- Originator JW Medical Systems
- Class Anti-infectives; Anti-inflammatories; Antiepileptic drugs; Antifungals; Antineoplastics; Cardiovascular therapies; Eye disorder therapies; Lactones; Macrolides; Nootropics; Polyenes; Pyridines; Skin disorder therapies
- Mechanism of Action Immunosuppressants; MTOR protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Coronary artery disease
- Phase II/III Coronary artery restenosis
Most Recent Events
- 26 Sep 2019 EXCEL-II sirolimus-eluting coronary stent is still in phase II/III trials for Coronary artery disease (Treatment-naive) and Coronary artery restenosis (Prevention) in China
- 12 Feb 2015 JW Medical systems completes enrolment in its phase II trial for Coronary artery disease (treatment naive) in China (9174729; NCT02057978)
- 12 Mar 2014 Phase-II clinical trials in Coronary artery disease (treatment-naive) in China (Intracoronary)